Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCLINE-AMI: Recaticimab in Acute Myocardial Infarction
NCT07290699Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 4 trial of recaticimab in acute myocardial infarction (AMI), sponsored by The Second Affiliated Hospital of Nanchang University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
recaticimab
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT07290699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290699.